Systemic and Nonrenal Adverse Effects Occurring in Renal Transplant Patients Treated with mTOR Inhibitors
The mammalian target of rapamycin inhibitors (mTOR-I), sirolimus and everolimus, are immunosuppressive drugs largely used in renal transplantation. The main mechanism of action of these drugs is the inhibition of the mammalian target of rapamycin (mTOR), a regulatory protein kinase involved in lymph...
Main Authors: | Gianluigi Zaza, Paola Tomei, Paolo Ria, Simona Granata, Luigino Boschiero, Antonio Lupo |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2013-01-01
|
Series: | Clinical and Developmental Immunology |
Online Access: | http://dx.doi.org/10.1155/2013/403280 |
Similar Items
-
Monoclonal Antibody Therapy and Renal Transplantation: Focus on Adverse Effects
by: Gianluigi Zaza, et al.
Published: (2014-02-01) -
mTOR-Inhibition and COVID-19 in Kidney Transplant Recipients: Focus on Pulmonary Fibrosis
by: Simona Granata, et al.
Published: (2021-08-01) -
Personalization of the Immunosuppressive Treatment in Renal Transplant Recipients: The Great Challenge in “Omics” Medicine
by: Gianluigi Zaza, et al.
Published: (2015-02-01) -
Naturally Occurring Compounds: New Potential Weapons against Oxidative Stress in Chronic Kidney Disease
by: Lorenzo Signorini, et al.
Published: (2017-07-01) -
Optimal management of acute nonrenal adverse reactions to iodine-based contrast media
by: Nielsen YW, et al.
Published: (2013-06-01)